Stem Cell Gene Therapy for Sickle Cell Disease

NCT02247843 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease

Interventions

BIOLOGICAL: βAS3-FB vector transduced peripheral blood CD34+ cells

Sponsor

Donald B. Kohn, M.D.

Collaborators

[object Object]